FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.